Edition:
United Kingdom

Alkermes Plc (ALKS.OQ)

ALKS.OQ on NASDAQ Stock Exchange Global Select Market

41.56USD
21 Sep 2018
Change (% chg)

$0.45 (+1.09%)
Prev Close
$41.11
Open
$41.15
Day's High
$42.39
Day's Low
$41.15
Volume
714,623
Avg. Vol
255,315
52-wk High
$71.22
52-wk Low
$38.23

Chart for

About

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central... (more)

Overall

Beta: 2.17
Market Cap(Mil.): $7,913.33
Shares Outstanding(Mil.): 153.66
Dividend: --
Yield (%): --

Financials

  ALKS.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.28 -- --
ROI: -12.81 1.79 14.61
ROE: -16.00 3.28 16.33

Recro Pharma shares plummet after FDA rejects non-opioid pain shot

Recro Pharma's shares dropped more than 50 percent on Thursday after the U.S. Food and Drug Administration declined to approve the drugmaker's non-opioid shot IV meloxicam, saying the pain-relieving effect did not meet expectations.

24 May 2018

UPDATE 2-Recro Pharma shares plummet after FDA rejects non-opioid pain shot

* FDA says drug's pain-relieving effect did not meet expectations

24 May 2018

BRIEF-Alkermes Q1 GAAP Loss Per Share $0.40

* Q1 REVENUE $225.2 MILLION VERSUS I/B/E/S VIEW $219.3 MILLION

26 Apr 2018

BRIEF-Alkermes Announces FDA Acceptance For Review Of New Drug Application For Alks 5461

* ALKERMES ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER

16 Apr 2018

BRIEF-Alkermes Says CEO's FY 2017 Total Compensation Was $9.4 Mln VS $9.6 Mln In FY 2016

* ALKERMES PLC SAYS CHAIRMAN AND CEO RICHARD POPS' FY 2017 TOTAL COMPENSATION WAS $9.4 MLN VS $9.6 MLN IN FY 2016 - SEC FILING Source text: (https://bit.ly/2GPYT4o) Further company coverage:

10 Apr 2018

BRIEF-Alkermes CEO Says Does Not Believe Additional Trials Of Depression Drug Necessary

* CEO SAYS "WE DON'T BELIEVE ANY ADDITIONAL CLINICAL TRIALS ARE NECESSARY" ON CONF CALL WHEN ASKED ABOUT FDA'S DECISION ON ITS DEPRESSION DRUG‍​ Further company coverage:

02 Apr 2018

FDA refuses to review Alkermes' depression treatment, seeks more trials

Alkermes Plc has been told to conduct more clinical trials of its experimental depression treatment after the U.S. Food and Drug Administration rejected its initial application for approval, citing a lack of evidence of its effectiveness.

02 Apr 2018

UPDATE 3-FDA refuses to review Alkermes' depression treatment, seeks more trials

* Shares fall as much as 22 percent (Adds comments from conference call; updates shares)

02 Apr 2018

FDA rejects application to review Alkermes' depression treatment

April 2 Alkermes Plc said on Monday the U.S. Food and Drug Administration rejected the application seeking approval for its experimental depression drug, citing insufficient evidence of effectiveness.

02 Apr 2018

BRIEF-Alkermes Receives Refusal To File Letter From FDA For ALKS 5461

* ALKERMES RECEIVES REFUSAL TO FILE LETTER FROM FDA FOR ALKS 5461

02 Apr 2018

Competitors

Earnings vs. Estimates